Quantitative analysis for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (64.0) (grade B). 29 signals analyzed (24 differentiated alt-data).
CTNM stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $12.52 | $11.81 | $12.04 |
| 2026-05-11 | $14.61 | $13.62 | $13.65 |
| 2026-05-21 | $14.43 | $13.21 | $14.37 |
| 2026-06-03 | $12.79 | $12.20 | $12.48 |
| 2026-06-15 | $12.92 | $11.74 | $12.72 |
| 2026-06-26 | $14.48 | $13.32 | $14.19 |
| 2026-07-09 | $15.84 | $15.23 | $15.45 |
| 2026-07-21 | $14.02 | $13.43 | $13.90 |
| 2026-07-31 | $16.08 | $14.13 | $15.49 |
| 2026-08-12 | $15.24 | $14.61 | $14.98 |
| 2026-08-24 | $17.24 | $16.23 | $16.63 |
| 2026-09-03 | $17.78 | $17.03 | $17.57 |
How Contineum Therapeutics, Inc. Class A Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $490M | — |
| IMMX | Immix Biopharma, Inc. | $486M | — |
| CBIO | Crescent Biopharma, Inc. | $521M | — |
| RLMD | Relmada Therapeutics, Inc. | $526M | 46.0 |
View all Health Care stocks by valuation and signals →
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) scores Buy (64.0), with no measured dimension below 51. Its highest are analyst consensus at 92, competitive moat at 87, technicals at 77, across 5 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 92 |
| competitive moat | 87 |
| technicals | 77 |
| valuation | 72 |
| earnings quality | 51 |
StoQuant analyzes 29 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Contineum Therapeutics, Inc. Class A Common Stock (CTNM): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CTNM"><img src="https://stoquant.com/badge/CTNM.svg" alt="Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.